Day One Biopharmaceuticals

DAWN

Börsenwert 2,22 Mrd. $

Acquisition expands Servier's position in oncology with tovorafenib marketed as OJEMDATM in the U.S . in pediatric low-grade glioma.

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Day One Biopharmaceuticals, Inc. (NasdaqGS: DAWN) to Servier. Under the terms of the proposed transaction, shareholders of Day One will receive $21.50 in cash for each share of Day One that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate,.

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers.

Day One's stock surges 66% after Servier agrees to acquire it for $21.50 per share in a $2.5B deal, adding brain tumor drug Ojemda and oncology pipeline assets.

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Day One Biopharmaceuticals, Inc. (NasdaqGS: DAWN) to Servier. Under the terms of the proposed transaction, shareholders of Day One will receive $21.50 in cash for each share of Day One that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate,.

The S&P 500 (^GSPC 1.33%) fell 1.33% to 6,740.02, the Nasdaq Composite (^IXIC 1.59%) slid 1.59% to 22,387.68, and the Dow Jones Industrial Average (^DJI 0.95%) dropped 0.95% to 47,501.55 as a weak jobs report and surging oil reinforced risk-off sentiment.

Bala Cynwyd, Pennsylvania--(Newsfile Corp. - March 6, 2026) - Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Day One Biopharmaceuticals, Inc. ("Day One" or the "Company") (NASDAQ: DAWN) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Servier for $21.50 per share in an all-cash transaction, representing a total equity value of approximately $2.5 billion. The investigation concerns whether the Day One Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company's shareholders.

MILWAUKEE, March 6, 2026 /PRNewswire/ -- Ademi LLP is investigating Day One (NASDAQ: DAWN) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Servier. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995.

Day One Biopharmaceuticals (NASDAQ: DAWN) ripped higher on Friday morning after Servier signed a definitive agreement to acquire the California-based firm for about $2.5 billion in cash. Servier's deal rewrites DAWN's technical profile, valuing its shares at $21.5 each, which translates to a nearly 70% upside from its previous close.

NEW YORK, March 6, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) related to its sale to Servier Pharmaceuticals LLC.